 | • レポートコード：GIR-23F3885 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界のPARP（ポリADP-リボースポリメラーゼ）阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 PARP（ポリADP-リボースポリメラーゼ）阻害剤市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・リムパーザ、ゼジューラ、ルブラカ、 タラゾパリブトシル酸塩、その他 アプリケーション別セグメントは次のように区分されます。 ・卵巣がん、乳がん、その他 世界のPARP（ポリADP-リボースポリメラーゼ）阻害剤市場の主要なマーケットプレーヤーは以下のとおりです。 ・AstraZeneca、Tesaro、Merck & Co、Clovis Oncology、Pfizer、GSK、Zai Lab 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の概要 - タイプ別分析（2017年vs2021年vs2028年）：リムパーザ、ゼジューラ、ルブラカ、 タラゾパリブトシル酸塩、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：卵巣がん、乳がん、その他 - 世界のPARP（ポリADP-リボースポリメラーゼ）阻害剤市場規模・予測 - 世界のPARP（ポリADP-リボースポリメラーゼ）阻害剤生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - AstraZeneca、Tesaro、Merck & Co、Clovis Oncology、Pfizer、GSK、Zai Lab ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：リムパーザ、ゼジューラ、ルブラカ、 タラゾパリブトシル酸塩、その他 ・アプリケーション別分析2017年-2028年：卵巣がん、乳がん、その他 ・PARP（ポリADP-リボースポリメラーゼ）阻害剤の北米市場分析 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の北米市場：タイプ別市場規模2017年-2028年 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・PARP（ポリADP-リボースポリメラーゼ）阻害剤のヨーロッパ市場分析 - ：PARP（ポリADP-リボースポリメラーゼ）阻害剤のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：PARP（ポリADP-リボースポリメラーゼ）阻害剤のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・PARP（ポリADP-リボースポリメラーゼ）阻害剤のアジア太平洋市場分析 - PARP（ポリADP-リボースポリメラーゼ）阻害剤のアジア太平洋市場：タイプ別市場規模2017年-2028年 - PARP（ポリADP-リボースポリメラーゼ）阻害剤のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・PARP（ポリADP-リボースポリメラーゼ）阻害剤の南米市場分析 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の南米市場：タイプ別市場規模2017年-2028年 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・PARP（ポリADP-リボースポリメラーゼ）阻害剤の中東・アフリカ市場分析 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - PARP（ポリADP-リボースポリメラーゼ）阻害剤の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The PARP (Poly ADP-Ribose Polymerase) Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size is estimated to be worth US$ 4822.1 million in 2021 and is forecast to a readjusted size of USD 8545.3 million by 2028 with a CAGR of 8.5% during review period. Ovarian Cancer accounting for % of the PARP (Poly ADP-Ribose Polymerase) Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Lynparza segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PARP (Poly ADP-Ribose Polymerase) Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Lynparza
Zejula
Rubraca
Talzenna
Other
Market segment by Application can be divided into
Ovarian Cancer
Breast Cancer
Other
The key market players for global PARP (Poly ADP-Ribose Polymerase) Inhibitor market are listed below:
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales, revenue and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor from 2019 to 2022.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
Chapter 13, 14, and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size & Forecast
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume (2017-2028)
1.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (2017-2028)
1.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity Analysis
1.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
1.6.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
1.6.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Tesaro
2.2.1 Tesaro Details
2.2.2 Tesaro Major Business
2.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck & Co
2.3.1 Merck & Co Details
2.3.2 Merck & Co Major Business
2.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Clovis Oncology
2.4.1 Clovis Oncology Details
2.4.2 Clovis Oncology Major Business
2.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 GSK
2.6.1 GSK Details
2.6.2 GSK Major Business
2.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Zai Lab
2.7.1 Zai Lab Details
2.7.2 Zai Lab Major Business
2.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Breakdown Data by Manufacturer
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in PARP (Poly ADP-Ribose Polymerase) Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2021
3.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2028)
4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028)
4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028)
4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2017-2028)
5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2017-2028)
6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2028)
7.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2028)
7.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
7.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2028)
8.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2028)
8.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
8.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
9.3.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2028)
10.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2028)
10.3 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
10.3.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
11.3.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of PARP (Poly ADP-Ribose Polymerase) Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of PARP (Poly ADP-Ribose Polymerase) Inhibitor
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Process
12.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Distributors
13.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 6. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Tesaro Basic Information, Manufacturing Base and Competitors
Table 8. Tesaro Major Business
Table 9. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 10. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 12. Merck & Co Major Business
Table 13. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 14. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 16. Clovis Oncology Major Business
Table 17. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 18. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 22. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. GSK Basic Information, Manufacturing Base and Competitors
Table 24. GSK Major Business
Table 25. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 26. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Zai Lab Basic Information, Manufacturing Base and Competitors
Table 28. Zai Lab Major Business
Table 29. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 30. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in PARP (Poly ADP-Ribose Polymerase) Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Site of Key Manufacturer
Table 36. PARP (Poly ADP-Ribose Polymerase) Inhibitor New Entrant and Capacity Expansion Plans
Table 37. PARP (Poly ADP-Ribose Polymerase) Inhibitor Mergers & Acquisitions in the Past Five Years
Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2017-2022) & (K Units)
Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2023-2028) & (K Units)
Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 42. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 43. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 44. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 45. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 46. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2017-2022) & (USD/Unit)
Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2023-2028) & (USD/Unit)
Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 49. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2017-2022) & (USD/Unit)
Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2023-2028) & (USD/Unit)
Table 54. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 55. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2023-2028) & (K Units)
Table 56. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 57. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 58. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 59. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 60. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 61. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 62. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 63. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2023-2028) & (K Units)
Table 64. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 67. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 68. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 69. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 78. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2022) & (K Units)
Table 79. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2023-2028) & (K Units)
Table 80. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 81. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 82. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 83. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 84. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 85. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2023-2028) & (K Units)
Table 94. PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material
Table 95. Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Distributors
Table 99. PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Customers
List of Figures
Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture
Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type in 2021
Figure 3. Lynparza
Figure 4. Zejula
Figure 5. Rubraca
Figure 6. Talzenna
Figure 7. Other
Figure 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application in 2021
Figure 9. Ovarian Cancer
Figure 10. Breast Cancer
Figure 11. Other
Figure 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2017-2028) & (K Units)
Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (2017-2028) & (USD/Unit)
Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity (2017-2028) & (K Units)
Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
Figure 19. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
Figure 20. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
Figure 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturer in 2021
Figure 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturer in 2021
Figure 23. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2028)
Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2017-2028)
Figure 28. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028) & (USD Million)
Figure 29. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028) & (USD Million)
Figure 31. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2017-2028) & (USD Million)
Figure 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2028)
Figure 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2017-2028)
Figure 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2017-2028) & (USD/Unit)
Figure 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2017-2028)
Figure 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2017-2028) & (USD/Unit)
Figure 39. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2028)
Figure 40. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 41. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2028)
Figure 42. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2028)
Figure 43. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2028)
Figure 47. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 48. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2028)
Figure 49. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2028)
Figure 50. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2017-2028)
Figure 59. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2028)
Figure 66. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 67. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2017-2028)
Figure 68. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2017-2028)
Figure 69. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2017-2028)
Figure 75. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2021
Figure 80. Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 81. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source